After rising 50% on Friday is Mesoblast now a good investment ahead of COVID-19 trials?

Mesoblast (ASX: MSB) (NASDAQ: MESO) was on our portfolio since May. However, volume started to climb higher this week as an advisory committee voted in favour of Mesoblasts pediatric drug remestemcel-L (Rynocil). The positive catalyst triggered a Mesoblast buying party on the ASX and the NASDAQ. For now, investors are optimistic about Mesoblast’s medium-long term […]

Gilead produces mixed COVID-19 trial results – investors now look to Mesoblast.

Biotechs universally share one mission. The industry aims to prevent or cure diseases to sustain a higher life expectancy. If a biotech successfully achieves its mission, humankind, the patients suffering, and investors all experience euphoria. However, if a biotech fails to develop a viable drug then the nightmarish scenario of people suffering continues. It seems […]

Mesoblast set to surge off COVID-19 stem cell trials.

The world is in dire need of a COVID-19 treatment. A vaccine is the plan b for the long-term. However, governments can take action immediately through COVID-19 treatments and testing. Mesoblast (NASDAQ:MESO) and (ASX:MSB), an Australian biotech is developing a stem cell treatment (Remestemcel-L), for COVID-19. The primary reason people die from COVID-19 is due […]